Does the media refer more to CNXU or DRIO?

In the previous week, Conexeu Sciences had 2 more articles in the media than DarioHealth. MarketBeat recorded 9 mentions for Conexeu Sciences and 7 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.64 beat Conexeu Sciences' score of -0.16 indicating that DarioHealth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conexeu Sciences 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral DarioHealth 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DRIO or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to DarioHealth's net margin of -192.23%. InfuSystem's return on equity of 2.78% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets DarioHealth -192.23% -60.52% -37.08% InfuSystem 1.12% 2.78% 1.41%

Does the media favor DRIO or INFU?

In the previous week, DarioHealth had 6 more articles in the media than InfuSystem. MarketBeat recorded 7 mentions for DarioHealth and 1 mentions for InfuSystem. DarioHealth's average media sentiment score of 0.64 beat InfuSystem's score of 0.00 indicating that DarioHealth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DarioHealth 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DRIO or KRMD?

In the previous week, DarioHealth had 4 more articles in the media than KORU Medical Systems. MarketBeat recorded 7 mentions for DarioHealth and 3 mentions for KORU Medical Systems. KORU Medical Systems' average media sentiment score of 0.65 beat DarioHealth's score of 0.64 indicating that KORU Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DarioHealth 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KORU Medical Systems 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LUCD or DRIO?

In the previous week, DarioHealth had 5 more articles in the media than Lucid Diagnostics. MarketBeat recorded 7 mentions for DarioHealth and 2 mentions for Lucid Diagnostics. DarioHealth's average media sentiment score of 0.64 beat Lucid Diagnostics' score of 0.45 indicating that DarioHealth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DarioHealth 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DRIO or PDEX?

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DarioHealth $22.36M 2.33 -$41.71M -$8.88 N/A Pro-Dex $66.59M 3.05 $8.98M $3.62 17.57

Is DRIO or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity. Company Net Margins Return on Equity Return on Assets DarioHealth -192.23% -60.52% -37.08% Pro-Dex 16.08% 22.78% 14.30%

DarioHealth (DRIO) Competitors

$7.10 -0.17 (-2.34%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$7.08 -0.01 (-0.21%)

As of 08/3/2026 04:01 PM Eastern

Compare

DRIO vs. CNXU, INFU, KRMD, LUCD, and PDEX

Should you buy DarioHealth stock or one of its competitors? MarketBeat compares DarioHealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DarioHealth include Conexeu Sciences (CNXU), InfuSystem (INFU), KORU Medical Systems (KRMD), Lucid Diagnostics (LUCD), and Pro-Dex (PDEX).

How does DarioHealth compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and DarioHealth (NASDAQ:DRIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Conexeu Sciences presently has a consensus target price of $20.00, suggesting a potential upside of 157.73%. DarioHealth has a consensus target price of $10.50, suggesting a potential upside of 47.89%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Conexeu Sciences is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

33.4% of DarioHealth shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Conexeu Sciences had 2 more articles in the media than DarioHealth. MarketBeat recorded 9 mentions for Conexeu Sciences and 7 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.64 beat Conexeu Sciences' score of -0.16 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Conexeu Sciences	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
DarioHealth	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Conexeu Sciences has higher earnings, but lower revenue than DarioHealth. Conexeu Sciences is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A
DarioHealth	$22.36M	2.33	-$41.71M	-$8.88	N/A

Conexeu Sciences has a net margin of 0.00% compared to DarioHealth's net margin of -192.23%. Conexeu Sciences' return on equity of 0.00% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
DarioHealth	-192.23%	-60.52%	-37.08%

Summary

Conexeu Sciences beats DarioHealth on 7 of the 12 factors compared between the two stocks.

How does DarioHealth compare to InfuSystem?

DarioHealth (NASDAQ:DRIO) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

DarioHealth has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, DarioHealth had 6 more articles in the media than InfuSystem. MarketBeat recorded 7 mentions for DarioHealth and 1 mentions for InfuSystem. DarioHealth's average media sentiment score of 0.64 beat InfuSystem's score of 0.00 indicating that DarioHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DarioHealth presently has a consensus price target of $10.50, indicating a potential upside of 47.89%. InfuSystem has a consensus price target of $15.00, indicating a potential upside of 62.69%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.33	-$41.71M	-$8.88	N/A
InfuSystem	$142.40M	1.31	$870K	$0.38	24.26

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InfuSystem has a net margin of 1.12% compared to DarioHealth's net margin of -192.23%. InfuSystem's return on equity of 2.78% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats DarioHealth on 13 of the 16 factors compared between the two stocks.

How does DarioHealth compare to KORU Medical Systems?

DarioHealth (NASDAQ:DRIO) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, DarioHealth had 4 more articles in the media than KORU Medical Systems. MarketBeat recorded 7 mentions for DarioHealth and 3 mentions for KORU Medical Systems. KORU Medical Systems' average media sentiment score of 0.65 beat DarioHealth's score of 0.64 indicating that KORU Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KORU Medical Systems	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KORU Medical Systems has higher revenue and earnings than DarioHealth. KORU Medical Systems is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.33	-$41.71M	-$8.88	N/A
KORU Medical Systems	$41.13M	4.72	-$2.64M	-$0.05	N/A

DarioHealth has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

KORU Medical Systems has a net margin of -5.27% compared to DarioHealth's net margin of -192.23%. KORU Medical Systems' return on equity of -13.61% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
KORU Medical Systems	-5.27%	-13.61%	-8.33%

DarioHealth presently has a consensus price target of $10.50, indicating a potential upside of 47.89%. KORU Medical Systems has a consensus price target of $7.25, indicating a potential upside of 71.39%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, analysts plainly believe KORU Medical Systems is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

KORU Medical Systems beats DarioHealth on 13 of the 16 factors compared between the two stocks.

How does DarioHealth compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and DarioHealth (NASDAQ:DRIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Lucid Diagnostics presently has a consensus target price of $4.19, indicating a potential upside of 332.41%. DarioHealth has a consensus target price of $10.50, indicating a potential upside of 47.89%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

DarioHealth has a net margin of -192.23% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
DarioHealth	-192.23%	-60.52%	-37.08%

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DarioHealth has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	41.75	-$58.01M	-$0.47	N/A
DarioHealth	$22.36M	2.33	-$41.71M	-$8.88	N/A

In the previous week, DarioHealth had 5 more articles in the media than Lucid Diagnostics. MarketBeat recorded 7 mentions for DarioHealth and 2 mentions for Lucid Diagnostics. DarioHealth's average media sentiment score of 0.64 beat Lucid Diagnostics' score of 0.45 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DarioHealth	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lucid Diagnostics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

Lucid Diagnostics and DarioHealth tied by winning 8 of the 16 factors compared between the two stocks.

How does DarioHealth compare to Pro-Dex?

DarioHealth (NASDAQ:DRIO) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Pro-Dex has a net margin of 16.08% compared to DarioHealth's net margin of -192.23%. Pro-Dex's return on equity of 22.78% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
Pro-Dex	16.08%	22.78%	14.30%

In the previous week, DarioHealth had 7 more articles in the media than Pro-Dex. MarketBeat recorded 7 mentions for DarioHealth and 0 mentions for Pro-Dex. DarioHealth's average media sentiment score of 0.64 beat Pro-Dex's score of 0.00 indicating that DarioHealth is being referred to more favorably in the media.

Company	Overall Sentiment
DarioHealth	Positive
Pro-Dex	Neutral

DarioHealth presently has a consensus price target of $10.50, indicating a potential upside of 47.89%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 10.05%. Given DarioHealth's higher probable upside, research analysts clearly believe DarioHealth is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

DarioHealth has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market.

Pro-Dex has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.33	-$41.71M	-$8.88	N/A
Pro-Dex	$66.59M	3.05	$8.98M	$3.62	17.57

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pro-Dex beats DarioHealth on 10 of the 15 factors compared between the two stocks.

Get DarioHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRIO vs. The Competition

Export

Metric	DarioHealth	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$53.38M	$1.37B	$6.86B	$12.44B
Dividend Yield	N/A	4.75%	2.60%	10.03%
P/E Ratio	-0.80	275.34	280.72	24.99
Price / Sales	2.33	62.84	588.10	90.57
Price / Cash	N/A	30.56	28.64	34.82
Price / Book	0.71	4.65	11.02	6.21
Net Income	-$41.71M	-$25.90M	$3.48B	$347.49M
7 Day Performance	-5.21%	-0.22%	0.80%	1.29%
1 Month Performance	-2.47%	-2.74%	-4.17%	-3.59%
1 Year Performance	-35.45%	-20.42%	61.47%	18.38%

DarioHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRIO DarioHealth	3.7238 of 5 stars	$7.10 -2.3%	$10.50 +47.9%	-35.4%	$53.38M	$22.36M	N/A	200	Upcoming Earnings
CNXU Conexeu Sciences	2.9337 of 5 stars	$7.97 +2.2%	$20.00 +151.1%	N/A	$213.15M	N/A	N/A	4	News Coverage Gap Up
INFU InfuSystem	4.0435 of 5 stars	$9.80 -1.2%	$15.00 +53.1%	+61.8%	$197.78M	$142.40M	163.36	410
KRMD KORU Medical Systems	3.4451 of 5 stars	$4.09 +2.0%	$7.25 +77.3%	+21.6%	$187.95M	$41.13M	N/A	80	Upcoming Earnings
LUCD Lucid Diagnostics	3.5073 of 5 stars	$0.91 0.0%	$4.19 +358.2%	-3.2%	$186.62M	$4.71M	N/A	70	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRIO) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DarioHealth (DRIO) Competitors

DRIO vs. CNXU, INFU, KRMD, LUCD, and PDEX

How does DarioHealth compare to Conexeu Sciences?

Summary

How does DarioHealth compare to InfuSystem?

Summary

How does DarioHealth compare to KORU Medical Systems?

Summary

How does DarioHealth compare to Lucid Diagnostics?

Summary

How does DarioHealth compare to Pro-Dex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DarioHealth (DRIO) Competitors

DRIO vs. CNXU, INFU, KRMD, LUCD, and PDEX

How does DarioHealth compare to Conexeu Sciences?

Do analysts rate CNXU or DRIO?

Do insiders & institutionals believe in CNXU or DRIO?

Does the media refer more to CNXU or DRIO?

Which has preferable valuation and earnings, CNXU or DRIO?

Is CNXU or DRIO more profitable?

Summary

How does DarioHealth compare to InfuSystem?

Which has more risk and volatility, DRIO or INFU?

Does the media favor DRIO or INFU?

Do analysts recommend DRIO or INFU?

Which has stronger valuation and earnings, DRIO or INFU?

Do institutionals and insiders have more ownership in DRIO or INFU?

Is DRIO or INFU more profitable?

Summary

How does DarioHealth compare to KORU Medical Systems?

Does the media refer more to DRIO or KRMD?

Which has stronger earnings and valuation, DRIO or KRMD?

Which has more risk & volatility, DRIO or KRMD?

Do institutionals & insiders have more ownership in DRIO or KRMD?

Is DRIO or KRMD more profitable?

Do analysts recommend DRIO or KRMD?

Summary

How does DarioHealth compare to Lucid Diagnostics?

Do analysts recommend LUCD or DRIO?

Is LUCD or DRIO more profitable?

Do institutionals and insiders have more ownership in LUCD or DRIO?

Which has stronger earnings and valuation, LUCD or DRIO?

Does the media favor LUCD or DRIO?

Which has more risk and volatility, LUCD or DRIO?

Summary

How does DarioHealth compare to Pro-Dex?

Is DRIO or PDEX more profitable?

Does the media prefer DRIO or PDEX?

Do analysts prefer DRIO or PDEX?

Which has more risk & volatility, DRIO or PDEX?

Which has preferable valuation and earnings, DRIO or PDEX?

Do institutionals & insiders believe in DRIO or PDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools